Updated:
BioMed Partners
BioMed Partners is a private equity firm based in Basel, Switzerland. It focuses on Venture Capital investments. The firm manages $389.26 million in assets,...
BioMed Partners
BioMed Partners is a private equity firm based in Basel, Switzerland. It focuses on Venture Capital investments. The firm manages $389.26 million in assets, with $4.89 million in available capital. It has a team of 7, including 6 investment professionals.
General information
Firm type
Private Equity
Location
Region
Europe
Country
Switzerland
City
Basel
Corporate office
Basel, Switzerland
Sector focus
Frequently asked questions
What stages does BioMed Partners target?
The firm invests from early-stage seed and start-up through expansion and late-stage growth. Its deal profile includes company creation around academic intellectual property, spin-offs from research institutions, and direct equity into more mature biotech platforms. This spans pre-clinical therapeutics to clinical-stage companies and commercial-stage medtech.
How does BioMed Partners source deal flow?
The firm leverages its Basel location, positioned within the Basel Area life sciences cluster that includes the University of Basel, ETH Zurich, and major pharmaceutical headquarters. Deal flow originates from academic research spin-offs, university technology transfer offices, and direct relationships with research hospitals. This proximity-driven model gives it early access to European life sciences innovation.
Which sectors does BioMed Partners focus on?
The firm concentrates on therapeutics, diagnostics, and medical technology, with additional activity in digital health. Its portfolio construction targets drug development platforms, precision medicine, and enabling technologies for healthcare delivery. It does not invest outside life sciences.
What is the geographic scope of BioMed Partners' investments?
The firm invests primarily in Switzerland, Germany, and neighboring European countries with established life sciences ecosystems. Its Basel base provides direct access to the Swiss biotech corridor, while its mandate extends to similar clusters across Western and Central Europe.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: